Subscribe to RSS
DOI: 10.1055/s-2003-43527
© Georg Thieme Verlag Stuttgart · New York
Medikamentöse Interaktionen in der Parkinson-Therapie
Drug Interactions in the Management of Parkinson's DiseasePublication History
Publication Date:
10 November 2003 (online)
![](https://www.thieme-connect.de/media/psychoneuro/200310/lookinside/thumbnails/10.1055-s-2003-43527-1.jpg)
Zusammenfassung
In der medikamentösen Therapie des Parkinson-Syndroms werden unterschiedliche Substanzgruppen eingesetzt. Diese können einerseits verschiedene unerwünschte Wirkungen haben, anderseits aber auch untereinander Interaktionen aufweisen. Da ein Großteil der Patienten wegen anderer Erkrankungen zusätzlich Präparate erhält, besteht eine Vielzahl weiterer Interaktionen, die viel relevanter sein können. Daraus ergeben sich unter Umständen Verstärkungen und Abschwächungen der individuellen Wirkung, bis zu lebensbedrohlichen Interaktionen. Dies ist bei der Therapie zu berücksichtigen.
Summary
A variety of different substances are currently used in the treatment of Parkinson's disease. These may be associated with a range of undesired effects, and also interact with one another. Since a large number of patients are also taking medication for co-existing conditions, numerous other interactions can occur that might be of even greater relevance. Consequent effects might be either augmentative or inhibitory in nature - even to the point of life-threatening interactions. Such a possibility must be taken into consideration when initiating treatment.
Key Words
parkinson's disease - drug interactions - side effects - levodopa
Literatur
- 1 Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry. 2002; 72 708-712
- 2 Bergman J, Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease. Clin Neuropharmacol. 2002; 25 107-110
- 3 Factor SA, Friedman JH, Lannon MC. et al. . Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial. Mov Disord. 2001; 16 135-139
- 4 Fernandez HH, Friedman JH, Jacques C, Rosenfeld M. Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord. 1999; 14 484-487
- 5 Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord. 2000; 15 201-211
- 6 Gimenez-Roldan S, Matio D, Navarro E, Gines MM. Efficacy and safety of clozapine and olanzapine: an open-label study comparing two groups of Parkinson's disease patients with dopaminergic-induced psychosis. Parkinsonism Relat Disord. 2001; 7 121-127
- 7 Heinonen EH, Myllyla V. Safety of selegiline (deprenyl) in the treatment of Parkinson's disease. Drug Saf. 1998; 19 11-22
- 8 Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs. 2001; 6 2163-2175
- 9 Kilpatrick IC, Traut M, Heal DJ. Monoamine oxidase inhibition is unlikely to be relevant to the risks associated with phentermine and fenfluramine: a comparison with their abilities to evoke monoamine release. Int J Obes Relat Metab Disord. 2001; 35 1454-1458
- 10 Pfeiffer C, Wagner ML. Clozapine therapy for Parkinson's disease and other movement disorders. Am J Hosp Pharm. 1994; 51 3047-3053
- 11 Shindler JS, Finnerty GT, Towlson K. et al. . Domperidone and levodopa in Parkinson's disease. Br J Clin Pharmacol. 1984; 18 959-962
- 12 Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs. 2002; 16 23-45
- 13 Van De Vijver DA, Roos RA, Jansen PA. et al. . Use of antipsychotics in Parkinson's disease in daily practice. Br J Clin Pharmacol. 2002; 53 551
- 14 Van de Vijver DA, Roos RA, Jansen PA. et al. . Influence of benzodiazepines on antiparkinsonian drug treatment in levodopa users. Acta Neurol Scand. 2002; 105 8-12
- 15 Verspohl EJ. Antiparkinsonmittel. In: Arzneimittelneben- und -wechselwirkungen: ein Handbuch und Tabellenwerk für Ärzte und Apotheker, Ammon HPT (Hrsg.), 4., neubearb. und erw. Auflage. Stuttgart: Wiss. Verlags-Gesellschaft. 2001;
Korrespondenzadresse
Prof. Dr. Wolfgang Jost
Fachbereich Neurologie, Deutsche Klinik für Diagnostik
Aukammallee 33
65191 Wiesbaden
Email: jost.neuro@dkd-wiesbaden.de